Hormonal treatment

PreclinicalSmall molecule

Bayer

Hormonal treatment is one of 10 small molecule programs targeting Menorrhagia. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MenorrhagiaActive, not recruiting

Cesarean Scar DefectCompleted

MenorrhagiaPreclinical

Active, not recruiting

Cesarean Scar DefectPreclinical

Completed

Competition

Competitive Landscape

11 competitors in Menorrhagia

#DrugCompanyPhaseTrials

Cyklokapron

JJ Molner

Approved

5 2

Danocrine

Cytotec

Jadelle

IItalian Network for Tumor Biotherapy Foundation

Approved

2 5

Orgovyx

Sumitomo Pharma America, Inc.

Estrasorb

Nuvaring

UUniversity of Washington

Preclinical

1 8

Dienogest

Bayer

Preclinical

—9

Norethisterone Acetate

MMansoura University

Preclinical

1 10

Hormonal treatment

Bayer

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Breast Cancer2 trials

Corneal Changes in Estrogen-Dependent Breast Cancer After Hormonal Treatment

Completed·SSohag University·Phase 4·NCT06924229·40 enrolled

Second-line Endocrine Treatment Followed by Capecitabine Versus Capecitabine Followed by Endocrine Treatment in Patients With Metastatic ER Positive Breast Cancer

Terminated·TThe Netherlands Cancer Institute·Phase 2/3·NCT00684216·10 enrolled

Prospective1 trial

A Prospective Randomized Phase III Study Comparing Hormonal Therapy +/-Docetaxel

Unknown status·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT00764166·254 enrolled

Prostate Cancer1 trial

Conformal Radiotherapy (CRT) Alone Versus CRT Combined With HDR BT or Stereotactic Body Radiotherapy for Prostate Cancer

Unknown status·MMaria Sklodowska-Curie National Research Institute of Oncology·Phase 3·NCT01839994·350 enrolled

Menorrhagia1 trial

MiCo - Mirena or Conventional Medical Treatment for Menorrhagia

Completed· Bayer logo

Bayer··NCT01085487·1,211 enrolled

Cesarean Scar Defect1 trial

Comparative Study Between Hormonal and Hysteroscopic Management of Cesarean Scar Defect

Completed·—·N/A·NCT06529952·78 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Hormonal treatment. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Hormonal treatment compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Hormonal treatment. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bayer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Bayer

Hormonal treatment

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Breast Cancer2 trials

Prospective1 trial

Prostate Cancer1 trial

Menorrhagia1 trial

Cesarean Scar Defect1 trial

References

Drug Info

Quick Facts

Related News